联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4220人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313741, encodeId=6c491313e41f6, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet：超短期联合治疗用于心脏术前贫血或孤立性缺铁患者, objectType=article, longId=167473, objectId=dff616e47337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dff616e47337, replyNumber=0, likeNumber=63, createdTime=2019-06-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dff616e47337, moduleTitle=Lancet：超短期联合治疗用于心脏术前贫血或孤立性缺铁患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dff616e47337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313740, encodeId=a62e1313e4065, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤, objectType=article, longId=166726, objectId=d16c166e26ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16c166e26ac, replyNumber=0, likeNumber=66, createdTime=2019-05-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16c166e26ac, moduleTitle=SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16c166e26ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313739, encodeId=e9641313e394f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetic Med：二甲双胍联合治疗新诊断的2型糖尿病患者的血糖控制持久性, objectType=article, longId=165688, objectId=32211656883e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32211656883e, replyNumber=0, likeNumber=54, createdTime=2019-05-10, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32211656883e, moduleTitle=Diabetic Med：二甲双胍联合治疗新诊断的2型糖尿病患者的血糖控制持久性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32211656883e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313738, encodeId=61181313e3861, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性, objectType=article, longId=165418, objectId=11561654182e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11561654182e, replyNumber=0, likeNumber=53, createdTime=2019-05-07, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11561654182e, moduleTitle=II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11561654182e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313737, encodeId=30e11313e3789, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=北大BMJ重磅！AIDS是降低全球健康期望寿命的首要原因！NEJM连发2文，PD-1/PD-L1联合治疗大PK！, objectType=article, longId=163567, objectId=d50316356e4c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50316356e4c, replyNumber=0, likeNumber=19, createdTime=2019-04-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50316356e4c, moduleTitle=北大BMJ重磅！AIDS是降低全球健康期望寿命的首要原因！NEJM连发2文，PD-1/PD-L1联合治疗大PK！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50316356e4c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313736, encodeId=1cc51313e36c1, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Galderma：新数据显示口服和局部联合治疗严重丘疹脓疱性红斑痤疮患者的临床益处, objectType=article, longId=161547, objectId=a8ea16154e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8ea16154e26, replyNumber=0, likeNumber=67, createdTime=2019-03-04, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8ea16154e26, moduleTitle=Galderma：新数据显示口服和局部联合治疗严重丘疹脓疱性红斑痤疮患者的临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8ea16154e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313735, encodeId=82851313e3540, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=FDA开始优先审查来那度胺与美罗华联合治疗淋巴瘤的潜力, objectType=article, longId=161426, objectId=ed5a161426e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed5a161426e0, replyNumber=0, likeNumber=76, createdTime=2019-03-02, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed5a161426e0, moduleTitle=FDA开始优先审查来那度胺与美罗华联合治疗淋巴瘤的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed5a161426e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313734, encodeId=fdd01313e3479, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=微芯生物与信达生物宣布合作开展晚期结直肠癌联合治疗的临床评估, objectType=article, longId=160430, objectId=d8d71604300d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d71604300d, replyNumber=0, likeNumber=72, createdTime=2019-02-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d71604300d, moduleTitle=微芯生物与信达生物宣布合作开展晚期结直肠癌联合治疗的临床评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d71604300d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313733, encodeId=ffdd1313e3359, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, objectType=article, longId=160409, objectId=dada1604094f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dada1604094f, replyNumber=0, likeNumber=62, createdTime=2019-02-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dada1604094f, moduleTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dada1604094f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313732, encodeId=d8a11313e32fa, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=AP&T：光动力疗法与全身化疗联合治疗难治型胆管癌的疗效分析, objectType=article, longId=160229, objectId=61a716022999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a716022999, replyNumber=0, likeNumber=56, createdTime=2019-02-18, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a716022999, moduleTitle=AP&T：光动力疗法与全身化疗联合治疗难治型胆管癌的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a716022999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313731, encodeId=ed441313e31bb, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Clin Gastroenterology H：钙调神经磷酸酶抑制剂和维多珠单抗联合治疗难治性炎症性肠病的安全性和有效性分析, objectType=article, longId=159757, objectId=7a7f159e5745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a7f159e5745, replyNumber=0, likeNumber=49, createdTime=2019-02-12, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a7f159e5745, moduleTitle=Clin Gastroenterology H：钙调神经磷酸酶抑制剂和维多珠单抗联合治疗难治性炎症性肠病的安全性和有效性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a7f159e5745)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313730, encodeId=b2fe1313e3064, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Chem Biol Interact：维生素K2和PTH联合治疗可以促进卵巢切除大鼠骨形成，增加体外成骨细胞分化, objectType=article, longId=158982, objectId=f19c15898270, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f19c15898270, replyNumber=0, likeNumber=60, createdTime=2019-01-28, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f19c15898270, moduleTitle=Chem Biol Interact：维生素K2和PTH联合治疗可以促进卵巢切除大鼠骨形成，增加体外成骨细胞分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f19c15898270)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313729, encodeId=a5b71313e2929, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, objectType=article, longId=158891, objectId=8a5b15889101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5b15889101, replyNumber=0, likeNumber=62, createdTime=2019-01-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5b15889101, moduleTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5b15889101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313728, encodeId=47d11313e2840, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Clin Gastroenterol H：氯吡格雷和低剂量阿司匹林单独或联合治疗可降低结直肠癌的风险, objectType=article, longId=156467, objectId=54bf15646e6d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54bf15646e6d, replyNumber=0, likeNumber=52, createdTime=2018-12-24, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54bf15646e6d, moduleTitle=Clin Gastroenterol H：氯吡格雷和低剂量阿司匹林单独或联合治疗可降低结直肠癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54bf15646e6d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313727, encodeId=01b91313e270a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Semin Arthritis Rheu：两种bDMARDs联合治疗类风湿性关节炎的安全性, objectType=article, longId=156410, objectId=2f321564100d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f321564100d, replyNumber=0, likeNumber=66, createdTime=2018-12-24, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f321564100d, moduleTitle=Semin Arthritis Rheu：两种bDMARDs联合治疗类风湿性关节炎的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f321564100d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313726, encodeId=59721313e26bd, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=IBD：粪便微生物移植与抗生素联合治疗可有效改善溃疡性结肠炎中拟杆菌的浓度, objectType=article, longId=154949, objectId=0563154949cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0563154949cc, replyNumber=0, likeNumber=52, createdTime=2018-12-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0563154949cc, moduleTitle=IBD：粪便微生物移植与抗生素联合治疗可有效改善溃疡性结肠炎中拟杆菌的浓度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0563154949cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313725, encodeId=b95e1313e2502, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估, objectType=article, longId=154784, objectId=d290154e847a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d290154e847a, replyNumber=0, likeNumber=63, createdTime=2018-12-02, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d290154e847a, moduleTitle=信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d290154e847a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313724, encodeId=f3c91313e2430, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, objectType=article, longId=154710, objectId=3672154e10c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3672154e10c1, replyNumber=0, likeNumber=23, createdTime=2018-12-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3672154e10c1, moduleTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3672154e10c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313723, encodeId=61a41313e234d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=CLIN CANCER RES：BRAF和HSP90抑制剂联合治疗不可切除的黑色素瘤, objectType=article, longId=154006, objectId=cf53154006f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf53154006f7, replyNumber=0, likeNumber=74, createdTime=2018-11-22, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf53154006f7, moduleTitle=CLIN CANCER RES：BRAF和HSP90抑制剂联合治疗不可切除的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf53154006f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313722, encodeId=670d1313e2214, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, objectType=article, longId=153843, objectId=27431538430e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27431538430e, replyNumber=0, likeNumber=20, createdTime=2018-11-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27431538430e, moduleTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27431538430e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet：超短期联合治疗用于心脏术前贫血或孤立性缺铁患者

2019-06-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤

2019-05-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetic Med：二甲双胍联合治疗新诊断的2型糖尿病患者的血糖控制持久性

2019-05-10

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性

2019-05-07

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

北大BMJ重磅！AIDS是降低全球健康期望寿命的首要原因！NEJM连发2文，PD-1/PD-L1联合治疗大PK！

2019-04-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Galderma：新数据显示口服和局部联合治疗严重丘疹脓疱性红斑痤疮患者的临床益处

2019-03-04

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

FDA开始优先审查来那度胺与美罗华联合治疗淋巴瘤的潜力

2019-03-02

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

微芯生物与信达生物宣布合作开展晚期结直肠癌联合治疗的临床评估

2019-02-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究

2019-02-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

AP&T：光动力疗法与全身化疗联合治疗难治型胆管癌的疗效分析

2019-02-18

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Clin Gastroenterology H：钙调神经磷酸酶抑制剂和维多珠单抗联合治疗难治性炎症性肠病的安全性和有效性分析

2019-02-12

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Chem Biol Interact：维生素K2和PTH联合治疗可以促进卵巢切除大鼠骨形成，增加体外成骨细胞分化

2019-01-28

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者

2019-01-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Clin Gastroenterol H：氯吡格雷和低剂量阿司匹林单独或联合治疗可降低结直肠癌的风险

2018-12-24

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Semin Arthritis Rheu：两种bDMARDs联合治疗类风湿性关节炎的安全性

2018-12-24

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

IBD：粪便微生物移植与抗生素联合治疗可有效改善溃疡性结肠炎中拟杆菌的浓度

2018-12-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

信达生物与和记黄埔医药宣布合作开展信迪利单抗与呋喹替尼用于实体瘤联合治疗的临床评估

2018-12-02

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点

2018-12-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

CLIN CANCER RES：BRAF和HSP90抑制剂联合治疗不可切除的黑色素瘤

2018-11-22

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌

2018-11-20

科室
- - 订阅+
  - 更多科室
工具
服务